Plague - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Plague - Pipeline Review, H2 2016

Plague - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Plague - Pipeline Review, H2 2016
Published Jul 13, 2016
70 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Plague - Pipeline Review, H2 2016, provides an overview of the Plague pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Plague
- The report reviews pipeline therapeutics for Plague by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Plague therapeutics and enlists all their major and minor projects
- The report assesses Plague therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Plague

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Plague
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners w

  
Source:
Document ID
GMDHC8273IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Plague Overview81
Therapeutics Development92
  Pipeline Products for Plague Overview91
  Pipeline Products for Plague Comparative Analysis101
Plague Therapeutics under Development by Companies111
Plague Therapeutics under Investigation by Universities/Institutes121
Plague Pipeline Products Glance133
  Clinical Stage Products131
  Early Stage Products141
  Unknown Stage Products151
Plague Products under Development by Companies161
Plague Products under Investigation by Universities/Institutes171
Plague Companies Involved in Therapeutics Development189
  Aradigm Corporation181
  AvidBiotics Corp.191
  Endacea, Inc.201
  Grifols, S.A.211
  iBio, Inc.221
  Mucosis B.V.231
  Syntiron LLC241
  Takeda Pharmaceutical Company Limited251
  Tetraphase Pharmaceuticals Inc.261
Plague Therapeutics Assessment2710
  Assessment by Monotherapy Products271
  Assessment by Combination Products281
  Assessment by Target292
  Assessment by Mechanism of Action312
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Drug Profiles3728
  (plague + small pox) vaccine Drug Profile371
  anthrax + plague vaccine Drug Profile381
  ARD-3100 Drug Profile394
  ARD-3150 Drug Profile435
  ciprofloxacin hydrochloride Drug Profile481
  L-97-1 Drug Profile492
  plague vaccine Drug Profile511
  plague vaccine Drug Profile521
  plague vaccine Drug Profile531
  plague vaccine Drug Profile541
  plague vaccine Drug Profile551
  plague vaccine Drug Profile561
  plague vaccine Drug Profile571
  plague vaccine 2 Drug Profile581
  pneumonic plaque vaccine Drug Profile591
  Recombinant Protein for Pneumonic Plague Drug Profile601
  Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague Drug Profile611
  TP-271 Drug Profile622
  Yersinia pestis vaccine Drug Profile641
Plague Dormant Projects651
Plague Discontinued Products661
Plague Product Development Milestones672
  Featured News &Press Releases671
    Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague671
    May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague681
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Plague - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Plague-Pipeline-Review-H2-2016-2088-16174>
  
APA:
Global Markets Direct - Market Research. (2016). Plague - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Plague-Pipeline-Review-H2-2016-2088-16174>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.